• Opinion
• [Reporter’s View] On MFDS’s new drug management team
• by Lee, Hye-Kyung Mar 6, 2024 06:03am

• Opinion
• [Reporter’s View] Long-awaited, but not prescribed?
• by Eo, Yun-Ho Feb 8, 2024 05:49am

• Opinion
• [Reporter’s View] Handling AI-collected ‘cancer info’
• by Kim, Jin-Gu Feb 6, 2024 06:10am

• Opinion
• [Desk’s View] New principles rouse moral responsibility
• by Lee, Tak-Sun Feb 6, 2024 06:10am

• Opinion
• [Reporter’s View] Restructuring in pharmaceutical industry
• by Son, Hyung-Min Feb 5, 2024 07:27pm

• Opinion
• [Reporter’s View] Conglomerates expanding into the pharma
• by Kim, Jin-Gu Jan 26, 2024 05:51am

• Opinion
• [Reporter’s View] KRPIA's new BOD signifies fresh starts
• by Eo, Yun-Ho Jan 25, 2024 05:49am

• Opinion
• [Reporter’s View] Supply disruptions disclosed in real-time
• by Lee, Hye-Kyung Jan 24, 2024 05:46am

• Opinion
• [Reporter’s View] Forxiga withdrawal raises concern
• by Son, Hyung-Min Jan 19, 2024 05:44am

• Opinion
• [Reporter’s View] HIRA's role in managing high-priced drugs
• by Kim, Jin-Gu Jan 15, 2024 05:36am